RUNX1 and myelodysplastic syndrome: While RUNX1 mutations are frequently associated with inferior responses to AML therapy, our analysis suggests that the poor outcomes seen in RUNX1 mutations occur primarily within younger patients treated with intensive therapeutic strategies, as well as the subgroup of RUNX1 mutant AML with prior MDS/MPN.